All Federal Grant Awards
Help

Project Grant R43NS124434

Award Date 9/24/22
Completion Date 8/31/24
Dollars Obligated $465K
Federal Agency
National Institute of Neurological Disorders and Stroke
Awardee
Axonis Therapeutics, Inc. (LR1MVZHCSJ95)
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
Project Grant R21NS135479
Logo for National Institute of Neurological Disorders and Stroke (HHS - NIH)
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $437,250 to the University of California, San Diego (UCSD) to conduct pooled in vivo screening of combination gene therapies for enhancing axonal regeneration after spinal cord injury (SCI). The key objectives are to 1) perform CRISPR screening to identify the most effective...
Project Grant R01NS132773
Logo for National Institute of Neurological Disorders and Stroke (HHS - NIH)
This $391,250 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program aims to develop effective therapeutic strategies for spinal cord injury (SCI) by evaluating controlled PTEN deletion and chondroitin sulfate proteoglycans (CSPGs) degradation to promote axon regeneration and functional recovery. The key objectives are to: 1) Temporally evaluate...
Project Grant R41NS137941
Logo for National Institute of Neurological Disorders and Stroke (HHS - NIH)
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is supporting research by Microcures Inc. to develop a nanoparticle-encapsulated small interfering RNA (siRNA) therapy targeting the Fidgetin-like 2 (FL2) protein. The goal is to promote tissue repair and functional recovery after spinal cord injury (SCI). The $458,154 award...
Project Grant R03HD114768
Logo for National Institute of Child Health and Human Development (HHS - NIH)
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $330,000 in funding to the Rehabilitation Institute of Chicago (doing business as Shirley Ryan AbilityLab) to conduct research aimed at improving walking function in individuals with chronic incomplete spinal cord injury (SCI). The key objectives of this 2-year project (8/1/2024 - 7/31/2026) are to: 1)...
Project Grant R21NS139109
Logo for National Institute of Neurological Disorders and Stroke (HHS - NIH)
This $184,837 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to develop a novel polymer-based drug delivery system for promoting spinal cord repair. The key objectives are to optimize an electrospray microsphere system for localized, sustained delivery of gabapentinoid drugs to the spinal cord lesion site, and to evaluate the...
Project Grant R44NS120397
Logo for National Institute of Neurological Disorders and Stroke (HHS - NIH)
The National Institute of Neurological Disorders and Stroke (NINDS), through the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded Versapeutics Inc. a $2,380,552 federal project grant on September 18, 2023 to conduct toxicology and efficacy studies of their novel antibody therapeutic Versamab-101 for treating spinal cord injury. Versapeutics, a for-profit biotechnology company, will utilize the funding to evaluate the safety profile and determine...
Project Grant K99HD117041
Logo for National Institute of Child Health and Human Development (HHS - NIH)
This $115,881 Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports research to evaluate the use of operant conditioning of the wrist extensor motor evoked potential (MEP) as a therapy to improve upper limb motor recovery in individuals with cervical spinal cord injury (SCI). The project aims to apply this non-invasive brain stimulation technique to target...
Project Grant F31NS135913
Logo for National Institute of Neurological Disorders and Stroke (HHS - NIH)
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $291,284 to Drexel University to conduct research on improving locomotion in spinal cord injury patients. The key objectives are to: Identify a population of inhibitory interneurons in the spinal cord that are involved in regulating proprioceptive sensory input to locomotor...
Project Grant R01NS140665
Logo for National Institute of Neurological Disorders and Stroke (HHS - NIH)
This $341,958 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research to define the contribution of the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF) and its downstream signaling to the development of chronic neuropathic pain after spinal cord injury (SCI). The key products and services to be delivered...
Project Grant R21NS135769
Logo for National Institute of Neurological Disorders and Stroke (HHS - NIH)
This $424,875.00 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund a comprehensive study of gene transcription patterns in diverse classes of neurons that connect the brain to the spinal cord after spinal cord injury in a mouse model. The research team at Marquette University will use single-cell sequencing technologies to profile...

DEVELOPMENT OF NEUROMODULATING AAV-KCC2 GENE THERAPY TO TREAT PARALYSIS, SPASTICITY AND NEUROPATHIC PAIN AFTER SPINAL CORD INJURY. - SUMMARY THERE ARE NO APPROVED THERAPIES FOR SPINAL CORD INJURY. THERE ARE ABOUT 300,000 PEOPLE LIVING WITH CHRONIC SPINAL CORD INJURY IN US. FOR THE VAST MAJORITY OF THEM, THE INJURY LEFT THEM INCAPABLE OF WALKING OR, IF THEY HAVE SUFFERED A CERVICAL SCI, ENTIRELY DEPENDENT UPON OTHERS FOR ASSISTANCE IN ALL OF THEIR ACTIVITIES OF DAILY LIVING FROM FEEDING TO PERSONAL CARE. WE ARE DEVELOPING A NEUROMODULATING GENE THERAPY FOR TREATING BOTH ACUTE AND CHRONIC SCI PATIENTS THAT WILL BE DELIVERED AS A SINGLE INJECTION TO SPINAL CORD. NEUROMODULATION AFTER INJURY HAS THE POTENTIAL TO RESTORE FUNCTIONAL RECOVERY, AS SHOWN BY A NUMBER OF DIFFERENT INVESTIGATORS. AFTER SCI THERE IS AN ELECTROCHEMICAL IMBALANCE THAT PREVENTS MOTOR NEURONS FROM ELICITING NORMAL MUSCLE ACTIONS THAT ARE CRITICAL FOR MOVEMENT OF ARMS AND LEGS. THIS IMBALANCE IS PARTLY CAUSED BY A DECREASE IN THE CHLORIDE TRANSPORTER CALLED KCC2. IT HAS BEEN SHOWN THAT BY RESTORING NORMAL LEVELS OF THIS TRANSPORTER IN SPARED SPINAL CORD NEURONS, PARALYZED MICE REGAIN WALKING ABILITY. FURTHERMORE, ENHANCEMENT OF KCC2 REDUCES PAIN AND SPASTICITY IN RODENT MODELS. THIS GRANT APPLICATION AIMS TO EXAMINE A NEW THERAPY THAT HAS THE POTENCY AND PROPERTIES TO BE TRANSLATED TOWARDS HUMAN CLINICAL STUDIES, BY TESTING THEM IN PRECLINICAL MODELS.

Posted 9/23/22, 12:00 AM